An interventional study of Ivosidenib and Gilteritinib in AML, Adult, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ivosidenib in Leukemia, Myeloid, Acute — 14 open to participants now, 19 under way, 4 of them phase 3. ivosidenib · Leukemia, Myeloid, Acute.
Among the 22 studies testing ivosidenib in Leukemia, Myeloid, Acute, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is the only one with no phase, reaches primary completion later than 14 of the 18 other live ones, and was the 16th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →14 of the 22 studies testing ivosidenib in Leukemia, Myeloid, Acute are open now, in 8 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Portugal, Spain
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 60+
Massachusetts General Hospital · Sites in United States
Ages 18–75
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
ivosidenib: first FDA approval 2018 (TIBSOVO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 4
First in 2014; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 537 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 72 across the 22 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 22 have an industry lead sponsor. The 10 most frequent:
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China: 29 open now, 32 under way, 5 of them phase 3. Of 9 finished, 0 (0%) have results posted.
Among the 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China, this one has the largest planned enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 with no phase, reaches primary completion later than 19 of the 31 other live ones, and was the 21st registered.
Institute of Hematology & Blood Diseases Hospital, China’s Leukemia, Myeloid, Acute studies by the year they started, since 2005.
9 of the studies testing ivosidenib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT02074839Institut de Recherches Internationales ServierStudy of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | 2026-12-31 |
| NCT03503409Groupe Francophone des MyelodysplasiesIDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | 2027-04-02 |
| NCT05756777Memorial Sloan Kettering Cancer CenterA Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | 2027-04-21 |
Add all 9 to your calendar (.ics) → With an account.
Among the 22 studies testing ivosidenib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Institute of Hematology & Blood Diseases Hospital, China’s 46 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.
Patients aged 14 years or older with diagnosed AML (non-M3) who have achieved complete remission in bone marrow morphology but are positive for minimal residual disease by flow cytometry or have the following genetic mutations that can be detected by PCR: NPM1 mutation, IDH1/2 mutation, DEK-NUP214 (DEK-CAN), RUNX1-RUNX1T1(AML 1-ETO), or CBFβ-MYH 11[4]. NGS can detect mutations such as FLT3.
For eligible patients, the treatment plan is selected by the doctor in charge according to the specific conditions of the patient. During the treatment, patients can have hematopoietic stem cell transplantation at any time.
This study compared relapse-free survival and overall survival of MRD-positive patients after effective and persistent MRD treatment, and based on the results, observed the efficacy and safety of different treatment regiments for MRD-positive AML patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ivosidenib 500mg/d: d1-28 ;Azacitidine 75mg/m2/d: d1-7;Venetoclax 600mg/d: d1-14
Drug: Ivosidenib · Drug: Venetoclax · Drug: Azacitidine
Gilteritinilb 120mg/d: d1-28; Venetocax 400mg/d: d1-7;Azacitidine 75mg/m2/d : d1-7
Drug: Gilteritinib · Drug: Venetoclax · Drug: Azacitidine
Azacitidine 75mg/m2/d: d1-7;Venetoclax400mg/d: d1-21 or Cytarabine 20mg/m2/d : d1-10;Venetoclax 600mg/d: d1-21
Drug: Venetoclax · Drug: Cytarabine · Drug: Azacitidine
Avapritinib 200mg/ day, 28 days a course; Azacitidine 75mg/m2/d: d1-7
Drug: Avapritinib · Drug: Azacitidine
Cytarabine 100mg/m2/d, d1-5; Daunorubicin 45mg/m2/d,d1-2; or Idarubicin 10mg/ m2/d,d1-2; or Mitoxantrone 8mg/ m2/d d1-2; Venetoclax 400mg d1-7
Drug: Venetoclax · Drug: Daunorubicin · Drug: Cytarabine · Drug: Idarubicin · Drug: Mitoxantrone
Cytarabine 100mg/ m2/d, d1-5; Homoharringtonine 2mg/ m2 d1-5; Venetoclax 400mg d1-7
Drug: Venetoclax · Drug: Cytarabine · Drug: Homoharringtonine
Azacitidine75 mg/m2 day1-7;Venetoclax 400mg day1-21 or,Cytarabine 20mg/m2 /day,day1-10; Venetoclax 600mg day1-21
Drug: Venetoclax · Drug: Cytarabine · Drug: Azacitidine
Azacitidine 75 mg/m² on days 1-7 Ruxolitinib 20 mg twice daily, 28-day cycle
Drug: Azacitidine · Drug: Ruxolitinib
Azacitidine 75 mg/m² on days 1-7 Tunlametinib 12 mg twice daily, 28-day cycle
Drug: Azacitidine · Drug: Trametinib
500mg d1-28
120mg d1-28
400mg d1-21 ; 400mg d1-7; 400mg d1-28; 600mg d1-14
200mg d1-28.
45mg/m2/d d1-2;
100mg/m2/d d1-5
10mg/m2/d d1-2
8mg/m2/d d1-2
2mg/m2/d d1-5
75mgd/m2 d1-7.
20 mg twice daily, 28-day cycle
12 mg twice daily, 28-day cycle
relapse-free survival rate
Time frame: up to 6 months
Measurable Residual Disease
Time frame: up to 6 months
Proportion of MRD turning negative
Time frame: up to 6 months
Overall survival(OS ) rate
Time frame: From the time the patients participated in the clinical trial until the patient died
Cumulative relapse rate
Time frame: From the time the patients participated in the clinical trial until the patient relapsed
Adverse Events (AEs)
Time frame: up to 2 years
The incidence of adverse events such as serious infections during treatment
Time frame: up to 2 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for May 2028, 47 months after the start.
Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 47 months is close to that.
Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ivosidenib · Gilteritinib · Venetoclax · Avapritinib · Daunorubicin · Cytarabine · Idarubicin · Mitoxantrone · Homoharringtonine · Azacitidine · Ruxolitinib · Trametinib
Institute of Hematology & Blood Diseases Hospital, China →